바이오 단백질 의약품 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global bio-protein drug market looks promising with opportunities in the pharma and biotech companies, cros, and academics markets. The global bio-protein drug market is expected to grow with a CAGR of 8.9% from 2025 to 2031. The major drivers for this market are the increasing demand for targeted therapies drives growth in bio-protein drugs. and the advancements in biotechnology enable the development of innovative bio-protein drugs.

• Lucintel forecasts that, within the type category, monoclonal antibodies is expected to witness higher growth over the forecast period.
• Within the application category, pharma and biotech companies is expected to witness the higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Bio-Protein Drug Market

The bio-protein drug market is evolving with key emerging trends that are reshaping its landscape. These trends include innovations in biosimilars, the rise of personalized medicine, and the integration of advanced technologies in drug discovery. As demand for biologics increases, these trends are expected to drive market growth, improve patient outcomes, and reduce healthcare costs ly.

• Growth of Biosimilars: The demand for biosimilars is increasing as they offer a more affordable alternative to expensive biologic drugs. Regulatory agencies around the world, including the FDA and EMA, have streamlined approval processes for biosimilars, promoting their use. As more biosimilars enter the market, competition is expected to reduce prices and make treatments more accessible to patients ly.
• Personalized Medicine: Personalized medicine, which tailors treatments based on genetic profiles, is gaining traction in the bio-protein drug market. This approach allows for more effective and targeted therapies, particularly in oncology and autoimmune diseases. The ability to deliver precision treatments is revolutionizing patient care, improving outcomes, and minimizing side effects associated with conventional therapies.
• Technological Advancements in Drug Discovery: The integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is transforming the bio-protein drug market. These technologies help in identifying potential therapeutic targets, optimizing drug design, and predicting patient responses. This is accelerating the development of new biologics and improving the efficiency of clinical trials.
• Expansion in Emerging Markets: Bio-protein drugs are increasingly being adopted in emerging markets, such as India and China, where there is a rising prevalence of chronic diseases. Cost-effective biosimilars and increased local production are making biologics more accessible in these regions. The growing middle class and healthcare reforms in these markets are expected to drive significant demand for bio-protein drugs.
• Collaboration and Strategic Partnerships: Pharmaceutical companies are increasingly forming partnerships with biotech firms and research institutions to co-develop innovative bio-protein drugs. These collaborations help companies to access new technologies, share research costs, and accelerate the commercialization of novel biologics. Strategic alliances are becoming a critical factor in staying competitive in the bio-protein drug market.

Emerging trends such as the growth of biosimilars, personalized medicine, AI-driven drug discovery, and strategic collaborations are reshaping the bio-protein drug market. These developments are making biologics more accessible, improving patient outcomes, and enhancing the efficiency of drug development, paving the way for a more innovative and sustainable future in the pharmaceutical industry.

Recent Developments in the Bio-Protein Drug Market

Recent developments in the bio-protein drug market reflect the increasing adoption of advanced biologic therapies and a focus on making treatments more affordable and accessible. Key innovations and regulatory changes are driving progress in the development and commercialization of bio-protein drugs across various therapeutic areas, including oncology, autoimmune diseases, and metabolic disorders.

• FDA Approval of New Monoclonal Antibodies: The approval of new monoclonal antibodies by the FDA has led to significant advancements in cancer immunotherapy. These biologics have shown efficacy in treating various cancers, including lymphoma and melanoma, and are part of a broader trend of expanding immunotherapy options in oncology. These approvals are paving the way for innovative treatments with fewer side effects compared to traditional chemotherapy.
• Advances in Gene and Cell Therapies: Gene and cell therapies are gaining traction in the bio-protein drug market, particularly in treating rare genetic disorders and cancers. Recent breakthroughs, such as CRISPR-based therapies and CAR-T cell treatments, are offering promising results. These therapies hold the potential to cure diseases at the genetic level, making them highly innovative in the treatment of previously untreatable conditions.
• Expansion of Biosimilars: The biosimilar market is expanding, with an increasing number of biosimilars entering the market across therapeutic areas such as oncology, rheumatology, and diabetes. These products are offering more affordable alternatives to branded biologics, which is especially important in emerging markets. The continued approval and uptake of biosimilars are making bio-protein drugs more accessible ly.
• Investment in Biotech Startups: Significant investment in biotech startups is driving the development of new bio-protein drugs. Venture capital and government grants are supporting innovation in biologics, particularly in areas such as personalized medicine and rare diseases. These investments are helping to accelerate the development of novel therapies and expand the pipeline of bio-protein drugs.
• Regulatory Changes and Faster Approvals: Regulatory bodies worldwide are streamlining the approval process for bio-protein drugs, particularly biosimilars and gene therapies. In the U.S. and Europe, initiatives have been introduced to speed up the review of novel biologics, reducing time to market. This trend is expected to facilitate faster access to life-saving therapies and encourage greater competition in the market.

Recent developments in the bio-protein drug market, such as FDA approvals for new monoclonal antibodies, the rise of gene and cell therapies, and the expansion of biosimilars, are transforming the treatment landscape. These advancements are driving innovation, making therapies more accessible, and accelerating the development of cutting-edge treatments for a wide range of diseases.

Strategic Growth Opportunities in the Bio-Protein Drug Market

The bio-protein drug market offers numerous growth opportunities, driven by increasing demand for biologics, advancements in biotechnology, and a focus on improving patient outcomes. Companies are capitalizing on these opportunities to develop innovative treatments for chronic and rare diseases while expanding into emerging markets.

• Oncology Treatments: The increasing demand for personalized cancer therapies presents a significant growth opportunity. Bio-protein drugs, including monoclonal antibodies and immune checkpoint inhibitors, are revolutionizing cancer treatment by offering more targeted and effective options. Continued investment in research and clinical trials for cancer therapies is expected to fuel the market's growth in oncology.
• Rheumatology and Autoimmune Diseases: Bio-protein drugs are seeing increasing adoption in treating autoimmune disorders such as rheumatoid arthritis, lupus, and psoriasis. The development of biologics like tumor necrosis factor (TNF) inhibitors and interleukin inhibitors is improving treatment outcomes. The growing prevalence of autoimmune diseases ly offers substantial opportunities for growth in this therapeutic area.
• Metabolic Disorders: Bio-protein drugs are becoming key treatments for metabolic disorders such as diabetes and obesity. Insulin analogs and growth hormone therapies are just a few examples of biologics being used to manage these conditions. As the prevalence of diabetes rises, there is a significant opportunity for bio-protein drugs to address this growing health challenge.
• Gene and Cell Therapy Innovations: Gene and cell therapies are a major area of growth, particularly for rare genetic diseases. The success of CAR-T cell therapies and gene editing technologies like CRISPR is driving the market. Companies investing in these therapies are positioned to capitalize on unmet medical needs and offer potential cures for conditions that were previously difficult or impossible to treat.
• Expansion in Emerging Markets: The growing middle class and healthcare reforms in emerging markets, such as China and India, offer a significant opportunity for the bio-protein drug market. With increased access to healthcare and a rising prevalence of chronic diseases, these regions are expected to see a surge in demand for biologics, including biosimilars.

Strategic growth opportunities in oncology, rheumatology, metabolic disorders, gene therapy, and emerging markets are reshaping the bio-protein drug landscape. These areas offer significant potential for market expansion, innovation, and addressing unmet medical needs, driving continued growth in the bio-protein drug market.

Bio-Protein Drug Market Driver and Challenges

The bio-protein drug market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory hurdles. Understanding these drivers and challenges is crucial for stakeholders to navigate the complex landscape and capitalize on growth opportunities.

The factors responsible for driving the Bio-protein Drug market include:

1. Technological Advancements: Advancements in biotechnology, such as gene editing, protein engineering, and monoclonal antibody development, are driving the growth of the bio-protein drug market. These innovations are leading to the development of more effective and targeted treatments, improving patient outcomes.

2. Rising Demand for Personalized Medicine: As healthcare moves toward personalized medicine, bio-protein drugs are becoming key in providing tailored treatments. Genetic profiling and biomarker-based therapies are enabling more precise and effective treatments, fueling the demand for biologics.

3. Aging Population: The growing aging population is driving the demand for bio-protein drugs, particularly in the treatment of chronic conditions like cancer, diabetes, and autoimmune diseases. Older adults are more likely to require long-term biologic therapies, expanding market opportunities.

4. Regulatory Support for Biologics: Regulatory bodies are providing faster approval pathways for biologics, including biosimilars and gene therapies. This is helping to accelerate the development and availability of bio-protein drugs, increasing their adoption ly.

5. Increasing Prevalence of Chronic Diseases: The rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, is creating a strong demand for bio-protein drugs. These conditions require long-term treatment, creating a sustained need for biologics.

Challenges in the Bio-protein Drug market are:

1. High Production Costs: The high production costs of bio-protein drugs, especially biologics like monoclonal antibodies and gene therapies, pose a significant challenge. These costs can limit access to treatments, particularly in low-income regions, and put pressure on healthcare systems.

2. Regulatory Hurdles: While regulatory bodies have made strides in approving biologics, navigating complex regulations in different markets remains a challenge for companies. Variations in approval processes across regions can delay market entry and increase development costs.

3. Intellectual Property Issues: Patent expirations and intellectual property disputes over biosimilars and innovative biologics can create legal barriers. Companies need to protect their innovations while also addressing the growing competition from biosimilars.

Technological advancements, demand for personalized medicine, and increasing chronic disease prevalence are key drivers of the bio-protein drug market. However, challenges such as high production costs, regulatory hurdles, and intellectual property issues need to be addressed for sustained growth and market expansion.

List of Bio-Protein Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bio-protein drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bio-protein drug companies profiled in this report include-

• Abbott Laboratories
• Bayer AG
• Eli Lilly and Company
• Amgen Inc.
• Biocon Ltd.
• Dr. Reddy'S Laboratories
• Roche

Bio-Protein Drug Market by Segment

The study includes a forecast for the global bio-protein drug market by type, application, and region.

Bio-Protein Drug Market by Type [Value from 2018 to 2031]:

• Monoclonal Antibodies
• Therapeutic Proteins
• Vaccines

Bio-Protein Drug Market by Application [Value from 2018 to 2031]:

• Pharma And Biotech Companies
• Cros
• Academics

Bio-Protein Drug Market by Region [Value from 2018 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Bio-Protein Drug Market

The bio-protein drug market is experiencing rapid growth due to advancements in biotechnology, increased demand for personalized medicine, and the rising prevalence of chronic diseases. Bio-protein drugs, which include monoclonal antibodies, enzymes, and hormones, are revolutionizing treatments in areas such as cancer, autoimmune disorders, and diabetes. The United States, China, Germany, India, and Japan are leading regions, each showing distinct developments and trends that are shaping the future of this dynamic market.

• United States: In the United States, the bio-protein drug market continues to grow, driven by advancements in immunotherapy, targeted treatments, and biosimilars. The Food and Drug Administration (FDA) has approved several new monoclonal antibodies and gene therapies, particularly for cancer and autoimmune diseases. Companies are focusing on developing personalized treatments tailored to genetic profiles. The increasing demand for biologics in the aging population and investments in biotech startups are fueling continued growth in this sector.
• China: China is emerging as a leader in the bio-protein drug market due to its rapid advancements in biotechnology and favorable regulatory reforms. The Chinese government has introduced policies that support research and development, and several homegrown biotech companies are making significant strides in developing biosimilars and monoclonal antibodies. With an increasing demand for biologics driven by rising chronic disease rates, China is poised to be a key player in the bio-protein drug market.
• Germany: Germany is a major hub for bio-protein drug development, with strong investments in research and manufacturing. The country's pharmaceutical and biotech sectors are focused on producing biosimilars, which are gaining traction due to their cost-effectiveness compared to original biologics. German companies are also leading efforts in the development of protein-based therapies for cancer, autoimmune diseases, and metabolic disorders. The integration of artificial intelligence and machine learning in drug development is expected to accelerate progress in Germany's bio-protein drug market.
• India: India's bio-protein drug market is expanding rapidly, with a focus on affordable and accessible biologic treatments. The country's thriving pharmaceutical sector is producing a wide range of biosimilars, which are crucial for treating diseases like cancer, diabetes, and rheumatoid arthritis. India has become a manufacturing hub for bio-protein drugs, thanks to its low-cost production capabilities and increasing investments in biotechnology. The Indian government is also supporting the sector with initiatives to improve healthcare accessibility across the population.
• Japan: Japan has a strong presence in the bio-protein drug market, with a focus on advanced biologics and monoclonal antibodies. The country's aging population is driving the demand for protein-based therapies, particularly in areas like cancer and diabetes treatment. Japanese companies are also exploring cutting-edge therapies, including gene and cell therapies, as part of the growing trend toward personalized medicine. Japan's efficient regulatory approval processes and high investment in healthcare are helping it maintain a competitive edge in the bio-protein drug sector.

Features of the Global Bio-Protein Drug Market

• Market Size Estimates: Bio-protein drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Bio-protein drug market size by type, application, and region in terms of value ($B).
• Regional Analysis: Bio-protein drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the bio-protein drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bio-protein drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the bio-protein drug market by type (monoclonal antibodies, therapeutic proteins, and vaccines), application (pharma and biotech companies, cros, and academics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Bio-Protein Drug Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Monoclonal Antibodies: Trends and Forecast (2019-2031)
• 4.4 Therapeutic Proteins: Trends and Forecast (2019-2031)
• 4.5 Vaccines: Trends and Forecast (2019-2031)

5. Global Bio-Protein Drug Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Pharma and Biotech Companies: Trends and Forecast (2019-2031)
• 5.4 CROs: Trends and Forecast (2019-2031)
• 5.5 Academics: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Bio-Protein Drug Market by Region

7. North American Bio-Protein Drug Market

• 7.1 Overview
• 7.2 North American Bio-Protein Drug Market by type
• 7.3 North American Bio-Protein Drug Market by application
• 7.4 United States Bio-Protein Drug Market
• 7.5 Mexican Bio-Protein Drug Market
• 7.6 Canadian Bio-Protein Drug Market

8. European Bio-Protein Drug Market

• 8.1 Overview
• 8.2 European Bio-Protein Drug Market by type
• 8.3 European Bio-Protein Drug Market by application
• 8.4 German Bio-Protein Drug Market
• 8.5 French Bio-Protein Drug Market
• 8.6 Spanish Bio-Protein Drug Market
• 8.7 Italian Bio-Protein Drug Market
• 8.8 United Kingdom Bio-Protein Drug Market

9. APAC Bio-Protein Drug Market

• 9.1 Overview
• 9.2 APAC Bio-Protein Drug Market by type
• 9.3 APAC Bio-Protein Drug Market by application
• 9.4 Japanese Bio-Protein Drug Market
• 9.5 Indian Bio-Protein Drug Market
• 9.6 Chinese Bio-Protein Drug Market
• 9.7 South Korean Bio-Protein Drug Market
• 9.8 Indonesian Bio-Protein Drug Market

10. ROW Bio-Protein Drug Market

• 10.1 Overview
• 10.2 ROW Bio-Protein Drug Market by type
• 10.3 ROW Bio-Protein Drug Market by application
• 10.4 Middle Eastern Bio-Protein Drug Market
• 10.5 South American Bio-Protein Drug Market
• 10.6 African Bio-Protein Drug Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Bio-Protein Drug Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Abbott Laboratories
  • Company Overview
  • Bio-Protein Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Bayer AG
  • Company Overview
  • Bio-Protein Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Eli Lilly and Company
  • Company Overview
  • Bio-Protein Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Amgen Inc.
  • Company Overview
  • Bio-Protein Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Biocon Ltd.
  • Company Overview
  • Bio-Protein Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Dr. Reddy'S Laboratories
  • Company Overview
  • Bio-Protein Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Roche
  • Company Overview
  • Bio-Protein Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us